Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zampieri, S
Right arrow Articles by van Venrooij, W J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zampieri, S
Right arrow Articles by van Venrooij, W J
Ann Rheum Dis 2001;60:72-76 ( January )

Concise report

Dephosphorylation of autoantigenic ribosomal P proteins during Fas-L induced apoptosis: a possible trigger for the development of the autoimmune response in patients with systemic lupus erythematosus S Zampieria, W Degena, A Ghiradellob, A Doriab, W J van Venrooija

a Department of Biochemistry, University of Nijmegen, PO Box 9101, NL-6500 HB Nijmegen, The Netherlands, b Division of Rheumatology, Department of Medical and Surgical Sciences, Via Giustiniani 2, 35128 Padova, Italy

Correspondence to: Professor van Venrooij W.vanvenrooij{at}bioch.kun.nl

Accepted for publication 31 May 2000

OBJECTIVES---Autoimmune diseases are characterised by the production of autoantibodies against various autoantigens. In the past few years data have been published on a possible role of apoptosis in the development of autoimmunity. These include the finding that several autoantigens become modified (for example, by cleavage) during apoptosis, and the observation that these modified antigens are translocated to the cell surface. When the normal clearance of apoptotic cells somehow is disturbed, such modified antigens might become exposed to the immune system. Because acidic ribosomal P (phospho-) proteins targeted by autoantibodies in systemic lupus erythematosus (SLE) are also concentrated at the surface of apoptotic cells, this study aimed at investigating what modifications occur on these antigens during apoptosis.
METHODS---Apoptosis in Jurkat cells was induced by Fas ligand (Fas-L), and the fate of autoantigenic P proteins was analysed in both normal and apoptotic total cell extracts.
RESULTS---The autoantigenic P proteins were not cleaved but dephosphorylated during Fas-L induced apoptosis. This dephosphorylation was prevented when caspase activity was inhibited.
CONCLUSIONS---As has been shown for other autoantigens targeted by autoantibodies in SLE, P proteins also are modified during apoptosis. P1 and P2 are completely dephosphorylated while P0 is partly dephosphorylated. Because the epitope targeted by autoantibodies normally is phosphorylated, it is possible that the apoptotic dephosphorylation of the antigen might be the trigger for the development of the autoimmune response against P proteins.


© 2001 by Annals of the Rheumatic Diseases



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
B. B. Cheung, J. Bell, A. Raif, A. Bohlken, J. Yan, B. Roediger, A. Poljak, S. Smith, M. Lee, W. D. Thomas, et al.
The Estrogen-responsive B Box Protein Is a Novel Regulator of the Retinoid Signal
J. Biol. Chem., June 30, 2006; 281(26): 18246 - 18256.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
R. Gerli and L. Caponi
Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients: reply
Rheumatology, September 1, 2003; 42(9): 1116 - 1117.
[Full Text] [PDF]


Home page
LupusHome page
J W. Dieker, J van der Vlag, and J H. Berden
Triggers for anti-chromatin autoantibody production in SLE
Lupus, December 1, 2002; 11(12): 856 - 864.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2001 BMJ Publishing Group Ltd & European League Against Rheumatism